| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 咨询技术 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 1/200 - 1/400 | Human,Mouse,Rat |
| Elisa | 1/10000 | Human,Mouse,Rat |
| Aliases | BCMA; TNFRSF17; BCM; TNFRSF13A |
| Entrez GeneID | 608 |
| clone | 1D12G9 |
| WB Predicted band size | 20.2kDa |
| Host/Isotype | Mouse IgG1 |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | Purified recombinant fragment of human BCMA (AA: QMAGQCSQNEYFDSLc) expressed in E. Coli. |
| Formulation | Purified antibody in PBS with 0.05% sodium azide |
+ +
以下是3篇与CD269(BCMA)抗体相关的代表性文献摘要：
1. **《Targeting BCMA in Multiple Myeloma: Advances from Antibody-Based Therapies》**
- 作者：N. Raje等
- 摘要：综述了靶向BCMA的抗体疗法(如单克隆抗体、双特异性抗体和抗体药物偶联物)在多发性骨髓瘤中的临床应用进展，强调其在复发/难治性患者中的显著疗效和潜在耐药机制。
2. **《Structural Basis of BLyS Receptor Recognition by Anti-BCMA Antibodies》**
- 作者：Y.T. Tai等
- 摘要：通过晶体结构分析揭示了抗BCMA抗体(如Belantamab mafodotin)与BCMA蛋白的结合表位，为优化抗体设计以增强靶向性和降低毒性提供了理论依据。
3. **《Phase I Study of Anti-BCMA CAR T Cells in Relapsed Myeloma》**
- 作者：D.M. Kranz等
- 摘要：报道了首个靶向BCMA的CAR-T细胞疗法(bb2121)的I期临床试验结果，证明其在复发/难治性多发性骨髓瘤患者中诱导深度缓解，并探讨了细胞因子释放综合征等副作用的管理策略。
4. **《BCMA-Specific Antibody-Drug Conjugate Induces Tumor Regression in Preclinical Models》**
- 作者：L. Zhou等
- 摘要：评估了一种新型BCMA抗体-药物偶联物(ADC)在动物模型中的抗肿瘤活性，显示其通过诱导DNA损伤和细胞凋亡显著抑制多发性骨髓瘤生长，支持进入临床转化研究。
注：以上文献为领域内典型研究方向示例，实际引用需核对具体论文信息。
CD269. also known as B-cell maturation antigen (BCMA), is a transmembrane protein encoded by the TNFRSF17 gene and belongs to the tumor necrosis factor receptor superfamily. It is primarily expressed on plasma cells and certain B-cell subsets, playing a critical role in B-cell development, survival, and immune regulation. BCMA binds to two ligands, BAFF (B-cell activating factor) and APRIL (a proliferation-inducing ligand), which activate signaling pathways like NF-κB, promoting cell proliferation and inhibiting apoptosis. Dysregulation of BCMA is implicated in hematologic malignancies, particularly multiple myeloma (MM), where its overexpression supports malignant plasma cell survival.
CD269 antibodies are therapeutic or diagnostic tools targeting this antigen. In MM therapy, anti-CD269 monoclonal antibodies (e.g., belantamab mafodotin) are designed as antibody-drug conjugates (ADCs) or bispecific antibodies to selectively eliminate malignant cells. Belantamab mafodotin, an ADC approved by the FDA in 2020. delivers a cytotoxic payload to BCMA-expressing cells. Bispecific antibodies, such as those engaging CD3 on T-cells, redirect immune cells to attack tumors. Additionally, BCMA is a key target in chimeric antigen receptor (CAR) T-cell therapies, showing remarkable efficacy in relapsed/refractory MM.
Research continues to optimize CD269-targeted therapies, addressing challenges like antigen escape and toxicity. These advancements highlight BCMA's significance in precision oncology and immunotherapy for B-cell malignancies.
×
